Dhotre SV, Dhotre PS, Rao A, Nagoba BS. When metabolic disease rewrites infection biology: Long-term multiorgan consequences of Helicobacter pylori infection in diabetes. World J Diabetes 2026; 17(5): 118333 [DOI: 10.4239/wjd.v17.i5.118333]
Corresponding Author of This Article
Basavraj S Nagoba, PhD, Assistant Dean, Professor, Department of Microbiology, Maharashtra Institute of Medical Sciences and Research (Medical College), Vishwanathpuram, Ambajogai Road, Latur 413531, Maharashtra, India. dr_bsnagoba@yahoo.com
Research Domain of This Article
Infectious Diseases
Article-Type of This Article
Opinion Review
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Shree V Dhotre, Department of Microbiology, Ashwini Rural Medical College, Hospital and Research Centre, Solapur 413006, Maharashtra, India
Pradnya S Dhotre, Department of Biochemistry, Ashwini Rural Medical College, Hospital and Research Centre, Solapur 413001, Maharashtra, India
Arunkumar Rao, Department of Orthopedics, MIMSR Medical College, Latur 413512, India
Basavraj S Nagoba, Department of Microbiology, Maharashtra Institute of Medical Sciences and Research (Medical College), Latur 413531, Maharashtra, India
Author contributions: Nagoba BS conceptualized and designed the study, developed the study outline, and coordinated manuscript preparation; Nagoba BS, Dhotre SV, Dhotre PS, and Rao A made substantial contributions to the study design, data interpretation, and critical discussion of the manuscript; Dhotre SV and Nagoba BS drafted, critically revised, and edited the manuscript for important intellectual content and contributed to the literature review; and all authors approved the final version of the manuscript to be published.
AI contribution statement: Any language refinement during manuscript preparation was limited to minor grammatical or readability improvements, without involvement in content generation, data analysis, or drafting of the manuscript.
Conflict-of-interest statement: All the authors report no relevant conflicts of interest for this article.
Corresponding author: Basavraj S Nagoba, PhD, Assistant Dean, Professor, Department of Microbiology, Maharashtra Institute of Medical Sciences and Research (Medical College), Vishwanathpuram, Ambajogai Road, Latur 413531, Maharashtra, India. dr_bsnagoba@yahoo.com
Received: December 30, 2025 Revised: February 11, 2026 Accepted: April 7, 2026 Published online: May 15, 2026 Processing time: 133 Days and 3.2 Hours
Abstract
The interaction between Helicobacter pylori (H. pylori) infection and diabetes mellitus has attracted increasing scientific attention over the past two decades, yet experimental evidence rigorously delineating causality and long-term organ-specific pathology has remained scarce. The study critically appraised herein addresses this important gap using a streptozotocin (STZ)-induced diabetic mouse model chronically infected with H. pylori and followed for 13 months. While this model yields valuable longitudinal insight into the infection-metabolism interface, the STZ-induced paradigm predominantly reflects insulin-deficiency-driven hyperglycemia rather than the insulin resistance-dominated pathophysiology characteristic of human type 2 diabetes mellitus; translational interpretation therefore warrants appropriate caution. By integrating metabolic monitoring, systematic histopathology, apoptosis assessment, virulence factor detection, and gut microbiota profiling, the investigators provide compelling evidence that diabetes fundamentally alters host-pathogen dynamics. H. pylori colonization is substantially prolonged, gastric inflammation progresses toward irreversibility, and progressive injury extends to the pancreas, liver, and kidneys, even as bacterial burden and hyperglycemia exhibit partial improvement over time. This article critically appraises the mechanistic plausibility, diagnostic relevance, and translational implications of these findings within the evolving framework of infection-driven metabolic and systemic disease. Current advances, controversies in the field, the authors’ perspectives, and priority directions for future research are also discussed.
Core Tip: This long-term experimental study demonstrates that diabetes transforms Helicobacter pylori infection from a largely gastric disease into a systemic pathological modifier. Prolonged colonization, persistent inflammation, extra-gastric dissemination of virulence factors, and compounded disruption of gut microbiota collectively drive irreversible multiorgan injury, even after partial improvement in bacterial load and glycemic status. These findings carry important implications for infection screening, eradication timing, and organ surveillance in diabetic patients, and open novel avenues for therapeutic intervention targeting the inflammation-microbiota-metabolic axis.
Citation: Dhotre SV, Dhotre PS, Rao A, Nagoba BS. When metabolic disease rewrites infection biology: Long-term multiorgan consequences of Helicobacter pylori infection in diabetes. World J Diabetes 2026; 17(5): 118333
The biological relationship between Helicobacter pylori (H. pylori) infection and diabetes mellitus represents one of the most clinically consequential yet mechanistically under-explored intersections in modern medicine. Both conditions are globally prevalent: H. pylori colonizes approximately half of the world’s population[1,2], while diabetes mellitus affects more than 537 million adults worldwide, with projections exceeding 780 million by 2045[3]. When these two disease states coexist, which they frequently do, the resulting host-pathogen interaction may diverge substantially from that observed in metabolically healthy individuals.
H. pylori is among the most successful chronic bacterial pathogens in human evolutionary history, having co-evolved with its host over millennia. Its persistence within the hostile gastric mucosa reflects sophisticated immune evasion strategies, including suppression of Th1 and Th17 responses, modulation of regulatory T-cells, and targeted interference with innate immune signaling[4,5]. Traditionally classified as a gastric pathogen responsible for gastritis, peptic ulcer disease, and gastric malignancy[6], accumulating evidence indicates that its systemic reach extends considerably further, encompassing cardiovascular, neurological, hepatic, and endocrine targets through chronic inflammation, immune modulation, and metabolic perturbation[7,8].
Diabetes mellitus provides a biological milieu uniquely permissive for amplifying infection-related pathology. Chronic hyperglycemia engenders impaired innate and adaptive immunity, oxidative stress, advanced glycation end-product accumulation, and dysregulated inflammatory signaling, all of which collectively tilt the host-pathogen balance toward microbial persistence and exuberant tissue injury[9,10]. Epidemiological studies have consistently reported higher H. pylori seroprevalence in individuals with type 2 diabetes, and have associated this co-occurrence with insulin resistance, poorer glycemic control, and increased risk of extra-gastric organ damage[11-13]. However, such observational data remain inherently limited by confounding variables, reverse causality, and their inability to establish mechanistic causality or temporal sequence.
In a recent landmark experimental study, Yang et al[1] deployed a streptozotocin (STZ)-induced diabetic mouse model chronically infected with H. pylori over 13 months to provide critical longitudinal evidence that diabetes fundamentally reshapes host-pathogen interactions, leading to persistent inflammation and irreversible multiorgan injury despite declining bacterial burden. This article critically appraises their findings, integrates them within the broader landscape of current evidence and ongoing controversies, delineates mechanistic plausibility, discusses clinical implications, and outlines priority directions for future research.
Animal models capable of interrogating long-term host-pathogen dynamics under metabolic stress are indispensable for advancing this field. Prior experimental work has largely focused on short-term gastric outcomes in immunocompetent hosts[14], leaving long-duration, metabolically stressed models underexplored. The STZ-induced model employed in the present study enables prolonged assessment of how diabetes alters H. pylori persistence, virulence expression, and extra-gastric pathology[15,16]. From a diagnostic microbiology perspective, this work reinforces the principle that host metabolic context profoundly shapes infection phenotype, challenging traditional pathogen-centric interpretive frameworks[17]. The key experimental findings of Yang et al[1], their mechanistic interpretations, and their principal clinical implications are summarized in Table 1.
Table 1 Summary of key experimental findings in Yang et al[1] and their mechanistic and clinical interpretation.
Experimental domain
Key finding
Proposed mechanism
Clinical implication
Gastric colonization
Prolonged H. pylori persistence in diabetic mice vs controls
Hyperglycemia impairs mucosal immunity, Th1/Th17 responses, and antimicrobial peptide expression
Diabetic patients may require extended or repeated eradication regimens
Gastric histopathology
Progressive submucosal inflammation and fibrosis; irreversible gastritis
The mechanistic strength of this study resides in its thoughtful use of the low-dose STZ protocol. This approach induces reversible beta-cell injury and sustained hyperglycemia without catastrophic pancreatic destruction, thereby modelling the chronic metabolic stress and downstream oxidative-inflammatory pathways most relevant to diabetic complications[15,16]. STZ-induced diabetes triggers mitochondrial superoxide overproduction, activation of the polyol and hexosamine pathways, and increased advanced glycation end-product formation, a unified mechanistic triad linking hyperglycemia to organ injury[18]. The 13-month observation window is particularly valuable, as it allows assessment of injury progression well beyond the resolution of peak hyperglycemia, a temporal depth rarely achieved in prior experimental infection models[14,19].
It is important to acknowledge, however, that the STZ model predominantly recapitulates insulin-deficient type 1 diabetes physiology rather than the insulin resistance-dominant landscape of type 2 diabetes mellitus. Since the vast majority of individuals with diabetes in whom H. pylori infection carries clinical relevance have type 2 disease, direct extrapolation of these findings requires careful qualification[20]. High-fat diet-induced or leptin receptor-deficient (db/db) mouse models in future studies would substantially strengthen translational relevance. A comparative overview of available animal models for studying H. pylori infection in the context of metabolic disease, including their respective strengths, limitations, and translational suitability, is presented in Table 2.
Table 2 Comparison of animal models for studying Helicobacter pylori infection in the context of metabolic disease.
Model
Metabolic phenotype
Strengths
Limitations
Suitability for H. pylori co-infection
Low-dose STZ mouse (current study)
Insulin deficiency; hyperglycemia
Reproducible; reversible beta-cell injury; established protocol; long-duration follow-up feasible
Models T1DM physiology; lacks insulin resistance; potential direct STZ organ toxicity
High-established for long-term H. pylori co-infection studies
Prolonged gastric colonization and irreversible gastritis
H. pylori persistence in diabetic hosts is biologically plausible through several well-characterized pathways. Hyperglycemia impairs neutrophil chemotaxis, phagocytic killing, and oxidative burst capacity, while simultaneously suppressing mucosal IgA secretion and antimicrobial peptide expression[21,22]. T-cell-mediated bacterial containment is further compromised, as chronic hyperglycemia skews the adaptive immune response away from effective Th1-driven bacterial clearance[23]. H. pylori itself actively exploit these deficiencies through CagA-mediated disruption of epithelial junctions and VacA-induced immune suppression, which are likely further amplified in the hyperglycemic milieu[4,5].
Prolonged colonization in this model was accompanied by progressive submucosal inflammation and fibrosis culminating in irreversible gastritis, a finding that aligns with human cohort data demonstrating accelerated gastric mucosal atrophy in diabetic individuals with H. pylori infection[24,25]. The inflammatory milieu is dominated by interleukin (IL)-6, tumor necrosis factor-alpha, and IL-1β, cytokines produced in excess under hyperglycemic conditions and known drivers of mucosal fibrogenesis[26,27]. This inflammatory architecture, once established, appears capable of self-propagation independently of active bacterial presence, a concept resonant with the broader literature on trained innate immunity and inflammatory memory[28].
Extra-gastric virulence factor dissemination and hepatic injury
The detection of H. pylori virulence factors within hepatic tissue represents perhaps the most paradigm-challenging finding of this study. Although H. pylori is not conventionally regarded as invasive or bacteraemic, emerging evidence supports multiple pathways of extra-gastric bacterial antigen delivery. Exosome-mediated systemic transport of the CagA oncoprotein has been mechanistically demonstrated[29], providing a biologically plausible vehicle for delivering virulence signals from the gastric mucosa to distant organs. Outer membrane vesicles represent an additional pathway, carrying lipopolysaccharide, peptidoglycan fragments, and heat-shock proteins capable of activating pattern recognition receptors in hepatic Kupffer cells[30,31].
Diabetes-associated intestinal barrier dysfunction, driven by tight junction protein degradation, mucosal oxidative stress, and dysbiosis-induced reduction in short-chain fatty acid (SCFA) production, plausibly facilitates portal translocation of these bacterial products[32,33]. Hepatic exposure to microbial antigens in a metabolically primed, steatotic liver further amplifies nuclear factor kappa B (NF-κB)-mediated inflammatory signalling, potentially accelerating progression of non-alcoholic fatty liver disease (NAFLD) toward non-alcoholic steatohepatitis[34,35]. Meta-analytic data from Mantovani et al[36] support an independent association between H. pylori infection and NAFLD risk, lending human epidemiological weight to the hepatic findings of this experimental model.
The stepwise mechanistic pathway from H. pylori infection under diabetic conditions to convergent multiorgan injury-encompassing impaired mucosal immunity, exosome-mediated virulence factor dissemination, hepatic NF-κB activation, renal podocyte injury, gut dysbiosis, and systemic apoptotic signaling-is depicted in Figure 1.
Figure 1 Proposed mechanistic pathway from Helicobacter pylori infection under diabetic conditions to multiorgan injury.
The stepwise pathway depicts: (1) Impaired mucosal immunity allowing prolonged gastric colonization; (2) Irreversible mucosal fibrosis and inflammation; (3) Exosome/outer membrane vesicles-mediated extra-gastric antigen translocation via the portal circulation; (4) Hepatic NF-κB activation and non-alcoholic fatty liver disease progression; (5) Renal cytokine-mediated podocyte injury; (6) Compounded microbiota dysbiosis with metabolic endotoxemia; and (7) Convergent systemic apoptotic signalling. NAFLD: Non-alcoholic fatty liver disease; OMV: Outer membrane vesicles; NASH: Non-alcoholic steatohepatitis; IL: Interleukin; TNF-α: Tumor necrosis factor-alpha; SCFA: Short-chain fatty acid; LPS: Lipopolysaccharide; H. pylori: Helicobacter pylori.
Gut microbiota disruption: Compounded dysbiosis and systemic consequences
Gut microbiota analysis represents one of the most integrative and forward-looking components of this study. Diabetes and H. pylori infection independently disrupt microbial ecology; their co-occurrence produces a compounded dysbiosis characterized by enrichment of potentially pathogenic taxa, depletion of beneficial SCFA-producing commensals, and markedly delayed microbial recovery[37,38]. SCFA deficiency impairs colonic epithelial integrity, reduces regulatory T-cell induction, and diminishes colonization resistance against enteric pathogens, creating a self-reinforcing cycle of barrier dysfunction and inflammatory amplification[39].
Dysbiosis-driven metabolic endotoxemia, characterized by elevated circulating lipopolysaccharide levels breaching a compromised gut barrier, has been mechanistically linked to insulin resistance, systemic low-grade inflammation, and progression of metabolic organ injury[40,41]. This pathway, first characterized by Cani et al[42], provides an important mechanistic bridge between gut microbiota disruption and the systemic organ pathology observed in this model. Emerging clinical evidence further supports this concept: H. pylori eradication in humans has been associated with partial microbiota restoration and modest improvements in glycemic markers[43,44], suggesting that the microbiota represents a therapeutically targetable intermediate in this pathological cascade.
Multiorgan apoptosis and infection-triggered inflammatory memory
Widespread apoptosis across the stomach, pancreas, liver, and kidney, persisting even after bacterial load reduction, provides mechanistic coherence to the observed multiorgan pathology. The Bcl-2 family-regulated intrinsic apoptotic pathway and the death receptor-mediated extrinsic pathway are both sensitized by inflammatory cytokines and reactive oxygen species produced in excess under diabetic conditions[45,46]. The convergence of metabolic stress, immune activation, and pathogen-derived pro-apoptotic signals creates a self-sustaining injury loop that renders tissue damage autonomous from the inciting infection.
The concept of trained innate immunity, whereby epigenetic reprogramming of innate immune cells following pathogen encounter results in persistent inflammatory sensitization[47], is directly applicable to this context. Monocytes, macrophages, and epithelial cells epigenetically imprinted by H. pylori virulence factors during prolonged diabetic infection may maintain exaggerated inflammatory responses long after microbiological eradication, driving the temporal dissociation between bacterial clearance and tissue injury observed in this model[28,47-49]. Future mechanistic work integrating transcriptomic profiling, chromatin accessibility assays, proteomics, metabolomics, and single-cell immune phenotyping will be essential to characterize these signatures across organ systems.
The convergence of metabolic stress, immune activation, and pathogen-derived pro-apoptotic signals creates a self-sustaining injury loop that renders tissue damage autonomous from the inciting infection, as illustrated schematically (Figure 2).
The epidemiological relationship between H. pylori infection and diabetes mellitus has been the subject of extensive investigation over the past decade. A meta-analysis by Mansori et al[50] pooling 26 case-control studies demonstrated a significantly elevated risk of diabetes among H. pylori-infected individuals (odds ratio = 1.72; 95%CI: 1.44-2.04). Jeon et al[11] longitudinally demonstrated a 1.5-fold increased rate of incident diabetes in H. pylori-infected older adults, and systematic reviews have consistently linked infection with insulin resistance metrics[12,13]. These associations are complicated, however, by substantial heterogeneity, publication bias, and the inability of observational designs to exclude reverse causality, since diabetes-related immune suppression may itself increase susceptibility to H. pylori acquisition and impaired eradication[51].
Conversely, evidence that H. pylori eradication improves glycemic parameters provides support for a causal role. Studies have demonstrated that successful H. pylori eradication was associated with significant reductions in HbA1c and fasting insulin in type 2 diabetic patients at 12 months. A subsequent similar study confirmed modest but consistent improvements in glycemic control following eradication[48,49], though the magnitude of benefit and its translation into clinically meaningful hard outcomes remain subjects of active debate.
Renal involvement: An emerging dimension
Renal injury observed in the Yang et al[1] experimental model, manifesting as tubular apoptosis and inflammatory infiltration, extends the pathological footprint of co-infection into an organ classically attributed to diabetic nephropathy through hemodynamic and metabolic pathways alone. Emerging clinical evidence supports this dimension. Epidemiological data suggest that H. pylori seropositivity is independently associated with proteinuria and reduced glomerular filtration rate in diabetic populations[52], and mechanistic studies implicate immune complex deposition, cytokine-mediated podocyte injury, and lipopolysaccharide-driven toll-like receptor activation in glomerulosclerosis progression[53]. The intersection of infection-driven renal inflammation with established diabetic nephropathy pathways likely creates a convergent injury mechanism more aggressive than either process alone.
Cardiovascular and neurological dimensions
Beyond the organ systems directly studied by Yang et al[1], the broader literature documents H. pylori-diabetes interactions with cardiovascular and neurological consequences. H. pylori infection has been associated with accelerated atherosclerosis, endothelial dysfunction, and increased risk of coronary artery disease, particularly in the diabetic context where vascular inflammation is already heightened[54,55]. CagA-positive strains specifically have been linked to elevated homocysteine levels, impaired endothelium-dependent vasodilation, and pro-thrombotic platelet activation[56]. The potential for H. pylori to modulate diabetic peripheral neuropathy through B12 malabsorption and inflammatory cytokine-mediated nerve damage adds yet another dimension to its systemic reach[57].
Virulence factor heterogeneity and pathological stratification
An important consideration in the broader field concerns the heterogeneity of H. pylori virulence factor profiles and their differential pathogenic impact. CagA-positive, VacA s1m1-producing strains are substantially more virulent than CagA-negative strains, producing greater gastric mucosal injury, more pronounced systemic inflammation, and stronger associations with gastric carcinogenesis[58,59]. Whether the hepatic virulence factor detection and multiorgan apoptosis observed in this model are strain-specific phenomena confined to highly virulent genotypes, or represent a more generalizable effect of infection under metabolic stress, remains a critical unresolved question. Future experimental designs should systematically compare CagA-positive vs CagA-negative strains in metabolically stressed hosts.
The major controversies and unresolved questions currently shaping the field of H. pylori infection and diabetes mellitus, together with the available evidence and priority research directions, are outlined in Table 3.
Table 3 Controversies and unanswered questions in the field of Helicobacter pylori infection and diabetes mellitus.
Controversy/question
Current evidence (for)
Current evidence (against/Limitations)
Research priority
Does H. pylori cause T2DM or is the association confounded?
Meta-analyses show increased T2DM risk with H. pylori infection[11-13]; eradication improves glycemic markers in some RCTs
Confounding by socioeconomic status, diet, obesity; bidirectional causality plausible
Mendelian randomization studies with large biobanks; long-term eradication RCTs with glycemic endpoints
Is hepatic virulence factor detection artefactual?
Exosome-mediated CagA delivery demonstrated in vitro[29]; NAFLD meta-analysis supports association[36]
Tissue contamination possible; causal pathway not fully established in vivo in humans
In vivo tracing studies with fluorescently tagged OMVs; human liver biopsy studies in H. pylori-positive diabetics
Does eradication reverse microbiota disruption?
Short-term restoration of some taxa post-eradication[43,44]; SCFA producers may recover
Antibiotic-associated dysbiosis may worsen microbiota short term; long-term data lacking
Longitudinal microbiome studies pre- and post-eradication in diabetic cohorts, with and without probiotics
Is the STZ model adequate to model T2DM-H. pylori interaction?
Validated platform for metabolic complications; reproducible hyperglycemia; feasible for mechanism discovery
Models T1DM physiology; lacks insulin resistance component; different inflammatory landscape from T2DM
High-fat diet, db/db, or ob/ob mouse models of H. pylori infection are needed for T2DM-relevant data
Therapeutic time window: When is eradication most effective?
Early eradication in H. pylori-positive T2DM patients associated with improved insulin sensitivity[48,49]
No RCT defines optimal timing relative to diabetes duration or infection stage
Staged RCTs stratifying by duration of diabetes and infection at time of eradication
Rethinking H. pylori as a systemic pathogen in diabetic hosts
Although derived from an animal model, the findings of Yang et al[1] carry substantive clinical implications that challenge established interpretive paradigms. The traditional framing of H. pylori as a localized gastric pathogen, where clinical management begins and ends with eradication, may be fundamentally inadequate in the diabetic context. In metabolically dysregulated hosts, H. pylori may function as a systemic inflammatory amplifier whose effects, once initiated, become partially autonomous from the inciting organism.
Epidemiological studies in humans have reported higher H. pylori prevalence among individuals with diabetes, and have associated this co-occurrence with insulin resistance, poorer glycemic control, and increased risk of hepatic and vascular complications[11,13,36]. These associations, viewed through the lens of the present experimental findings, suggest a more nuanced paradigm: The inflammatory phenotype and temporal trajectory of infection, rather than mere colonization status, may carry greater clinical significance than seroprevalence alone. Importantly, diabetes itself drives progressive multiorgan injury through independent metabolic, oxidative, and hemodynamic mechanisms; disentangling infection-specific contributions from these established pathways will require carefully controlled prospective studies with repeated organ function assessments and biomarker profiling[60].
The temporal dissociation principle and its clinical corollary
The temporal dissociation between declining bacterial burden and ongoing tissue injury observed in this model represents what may be the most clinically actionable finding of the study. This observation directly cautions against the clinical heuristic of equating microbiological eradication with biological resolution. In diabetic patients who achieve H. pylori eradication confirmed by urea breath test or stool antigen testing, current practice typically regards the infection episode as closed. The present experimental evidence suggests this approach may be insufficient in metabolically vulnerable hosts, where infection-triggered inflammatory cascades may become self-sustaining, continuing to drive organ damage despite microbiological cure[28,47].
Furman et al[60] have characterized chronic inflammation as a fundamental driver of disease across organ systems throughout the lifespan, a framework within which infection-primed, metabolically amplified inflammation fits naturally. The present findings operationalize this concept with longitudinal experimental data, demonstrating that organ injury continues to accrue on a biological timescale that outlasts the microbiological one.
The therapeutic time window and early intervention strategies
The concept of a therapeutic time window, within which early eradication before inflammatory cascades become self-sustaining could yield fundamentally different biological outcomes, represents one of the most clinically important hypotheses arising from this work[61]. Evidence in support of early intervention includes randomised controlled trial (RCT) data demonstrating greater glycemic benefit from eradication in patients with shorter diabetes duration[48,49], and observational data suggesting that eradication prior to significant mucosal atrophy prevents progression to gastric preneoplastic lesions[62]. In the context of the infection-diabetes interaction, early eradication combined with glycemic optimization may prevent the establishment of the self-reinforcing inflammatory loop observed in this experimental model.
Adjunctive strategies targeting the microbiota-inflammation axis, including Lactobacillus and Bifidobacterium containing probiotic supplementation, prebiotic dietary modification, and anti-inflammatory agents, warrant systematic evaluation in diabetic individuals undergoing H. pylori eradication[44,63]. These approaches might accelerate microbiota resilience, reduce post-eradication antibiotic-associated dysbiosis, and blunt residual inflammatory signaling that persists after microbiological cure. Prospective clinical trials evaluating whether H. pylori eradication in diabetic hosts modifies systemic inflammatory biomarkers, microbiota composition, or progression of organ-specific injury would provide critical translational validation of these experimental observations.
Screening, monitoring, and surveillance implications
The prominent hepatic and renal involvement observed in this experimental model reinforces the need for broadened clinical vigilance in diabetic patients with current or prior H. pylori infection. Current clinical guidelines for H. pylori management focus primarily on gastroduodenal outcomes: Peptic ulcer disease, gastric mucosa-associated lymphoid tissue lymphoma, and cancer risk reduction[64]. The evidence base for systematic extra-gastric organ monitoring in infected diabetic individuals remains limited, yet the experimental and epidemiological data increasingly support its consideration, particularly in patients with long-standing metabolic dysregulation, suboptimal glycemic control, or established microvascular complications.
Periodic hepatic function assessment, urine albumin-to-creatinine ratio monitoring, and non-invasive fibrosis markers in diabetic patients with prior H. pylori infection represent pragmatic, low-cost surveillance strategies that could be incorporated into existing diabetic complication monitoring pathways pending prospective validation[65]. Active universal H. pylori screening in newly diagnosed type 2 diabetic patients, analogous to existing protocols for microalbuminuria and retinopathy, merits serious consideration as a means of identifying individuals at elevated risk for infection-amplified organ injury.
Based on the foregoing experimental and clinical evidence, a stepwise management algorithm integrating universal screening, virulence genotyping, early eradication with glycemic co-optimization, probiotic adjunction, and post-eradication multiorgan surveillance is proposed for H. pylori-infected patients with type 2 diabetes mellitus Figure 3.
Figure 3 Proposed clinical algorithm for Helicobacter pylori management in patients with type 2 diabetes mellitus.
A stepwise algorithm is proposed integrating: (1) Universal Helicobacter pylori screening at type 2 diabetes mellitus diagnosis; (2) Virulence genotyping (CagA/VacA) for risk stratification; (3) Early eradication with glycemic co-optimization; (4) Probiotic adjunction for microbiota resilience; and (5) Post-eradication multiorgan surveillance encompassing hepatic function, renal parameters, and HbA1c. H. pylori: Helicobacter pylori; T2DM: Type 2 diabetes mellitus; ALT: Alanine aminotransferase; UBT: Urea breath test; LFT: Liver function test; uACR: Urine albumin-to-creatinine ratio; eGFR: Estimated glomerular filtration rate.
AUTHORS’ PERSPECTIVES
In our view, the work of Yang et al[1] represents a meaningful experimental advance that reframes H. pylori infection in diabetic hosts from a localized, reversible gastric disease to a potentially systemic, partially irreversible pathological process. Several perspectives that we believe deserve particular emphasis emerge from our appraisal.
First, the field requires a conceptual shift from infection-centric to host-centric management frameworks. The metabolic context in which H. pylori infection is encountered, more than the infection alone, may be the primary determinant of long-term organ outcomes. This suggests that glycemic optimization must be regarded as an integral rather than incidental component of H. pylori management in diabetic patients.
Second, we believe the temporal dissociation between microbiological cure and biological resolution, if validated in human cohorts, would necessitate a redesign of post-eradication follow-up protocols. Current clinical practice largely equates eradication confirmation with case closure; a paradigm in which serial biomarker and organ function monitoring extends well beyond the point of microbiological cure would represent a substantive but evidence-supported evolution in management.
Third, the gut microbiota emerges from this work as a therapeutically targetable intermediate sitting at the intersection of metabolic disease, infection biology, and systemic inflammation. We anticipate that microbiota-directed adjunctive therapies will feature prominently in future clinical trial designs evaluating H. pylori management in diabetic populations.
Fourth, virulence factor profiling of infecting H. pylori strains, currently not routine in clinical diagnostic microbiology, may gain importance as a tool for stratifying risk of extra-gastric organ injury in diabetic patients. CagA and VacA genotyping could potentially identify individuals at highest risk, warranting more intensive monitoring and earlier eradication.
FUTURE RESEARCH DIRECTIONS
Model diversification
Future experimental studies should deploy type 2 diabetes mellitus-relevant animal models, including high-fat diet-induced obesity, db/db mice, and ob/ob mice, to confirm and extend the findings of Yang et al[1] in an insulin resistance-dominated metabolic context. Comparative studies across STZ, high-fat diet, and genetic obesity models using identical H. pylori infection protocols would substantially strengthen translational confidence.
Human translational cohorts
Prospective observational cohorts enrolling newly diagnosed type 2 diabetes mellitus patients with and without H. pylori infection and following them longitudinally for hepatic, renal, and cardiovascular outcomes, with serial microbiome, biomarker, and histological sampling, would provide the human validation that experimental models alone cannot offer.
Eradication timing RCTs
Randomized controlled trials stratifying diabetic patients by duration of both H. pylori infection and diabetes at the time of eradication would test the therapeutic time window hypothesis and identify optimal intervention points. These trials should incorporate multiorgan function endpoints beyond standard gastroduodenal outcomes.
Microbiota-targeted adjunctive therapies
Clinical trials evaluating probiotic supplementation, prebiotic dietary modification, and fecal microbiota transplantation as adjuncts to eradication therapy in type 2 diabetes mellitus patients would directly test whether microbiota restoration attenuates post-eradication residual inflammation and organ injury progression.
Epigenetic and molecular characterization
Integrating transcriptomics, epigenomics, proteomics, and single-cell immune phenotyping into experimental co-infection models would characterize the molecular basis of infection-triggered inflammatory memory and identify candidate targets for pharmacological interruption of self-sustaining injury cascades.
Virulence genotype stratification
Systematic comparison of CagA-positive vs CagA-negative and VacA s1m1 vs s2m2 strains in STZ and type 2 diabetes mellitus mouse models would clarify whether extra-gastric organ injury is a strain-dependent or generalizable phenomenon of metabolically stressed hosts.
CONCLUSION
This experimental study provides important longitudinal evidence that diabetes fundamentally reshapes the biology of H. pylori infection, transforming what is typically a manageable gastric disorder into a systemic pathological modifier capable of driving irreversible multiorgan injury. The study’s most significant contributions lie in its demonstration that early infection-triggered inflammatory cascades persist and drive progressive tissue damage across the pancreas, liver, and kidneys even when hyperglycemia and bacterial burden show partial improvement; that virulence factors disseminate to extra-gastric organs through mechanisms plausibly linking the gut-liver axis to systemic disease; and that compounded microbiota disruption represents a biologically active and potentially modifiable intermediate in the pathological cascade.
For clinicians, diagnostic microbiologists, and diabetologists, the core message is one of expanded clinical responsibility: In diabetic hosts, H. pylori infection warrants early detection, timely eradication, glycemic co-optimization, and sustained multiorgan vigilance. Microbiological cure alone may be insufficient to prevent downstream organ pathology once inflammatory thresholds have been crossed, underscoring the urgency of early intervention and thoughtful post-eradication follow-up.
While the STZ model carries important translational limitations, most notably its insulin-deficiency phenotype rather than insulin resistance, the breadth of its findings, the rigor of its longitudinal design, and the mechanistic coherence of its results collectively establish it as a meaningful contribution to this evolving field. The challenge now is to translate these experimental observations into human cohort studies and clinical trial designs that can validate the therapeutic time window hypothesis, define optimal surveillance strategies, and ultimately reshape the clinical management of H. pylori infection in the large and growing global population of diabetic individuals.
Gravina AG, Zagari RM, De Musis C, Romano L, Loguercio C, Romano M. Helicobacter pylori and extragastric diseases: A review.World J Gastroenterol. 2018;24:3204-3221.
[PubMed] [DOI] [Full Text]
Asano N, Imatani A, Watanabe T, Fushiya J, Kondo Y, Jin X, Ara N, Uno K, Iijima K, Koike T, Strober W, Shimosegawa T. Cdx2 Expression and Intestinal Metaplasia Induced by H. pylori Infection of Gastric Cells Is Regulated by NOD1-Mediated Innate Immune Responses.Cancer Res. 2016;76:1135-1145.
[RCA] [PubMed] [DOI] [Full Text][Cited by in Crossref: 65][Cited by in RCA: 63][Article Influence: 6.3][Reference Citation Analysis (0)]
Delamaire M, Maugendre D, Moreno M, Le Goff MC, Allannic H, Genetet B. Impaired leucocyte functions in diabetic patients.Diabet Med. 1997;14:29-34.
[PubMed] [DOI] [Full Text]
Moutschen MP, Scheen AJ, Lefebvre PJ. Impaired immune responses in diabetes mellitus: analysis of the factors and mechanisms involved. Relevance to the increased susceptibility of diabetic patients to specific infections.Diabete Metab. 1992;18:187-201.
[PubMed] [DOI]
Shimoda A, Ueda K, Nishiumi S, Murata-Kamiya N, Mukai SA, Sawada S, Azuma T, Hatakeyama M, Akiyoshi K. Exosomes as nanocarriers for systemic delivery of the Helicobacter pylori virulence factor CagA.Sci Rep. 2016;6:18346.
[PubMed] [DOI] [Full Text]
Thaiss CA, Levy M, Grosheva I, Zheng D, Soffer E, Blacher E, Braverman S, Tengeler AC, Barak O, Elazar M, Ben-Zeev R, Lehavi-Regev D, Katz MN, Pevsner-Fischer M, Gertler A, Halpern Z, Harmelin A, Aamar S, Serradas P, Grosfeld A, Shapiro H, Geiger B, Elinav E. Hyperglycemia drives intestinal barrier dysfunction and risk for enteric infection.Science. 2018;359:1376-1383.
[RCA] [PubMed] [DOI] [Full Text][Cited by in Crossref: 809][Cited by in RCA: 701][Article Influence: 87.6][Reference Citation Analysis (0)]
Rinella ME, Lazarus JV, Ratziu V, Francque SM, Sanyal AJ, Kanwal F, Romero D, Abdelmalek MF, Anstee QM, Arab JP, Arrese M, Bataller R, Beuers U, Boursier J, Bugianesi E, Byrne CD, Castro Narro GE, Chowdhury A, Cortez-Pinto H, Cryer DR, Cusi K, El-Kassas M, Klein S, Eskridge W, Fan J, Gawrieh S, Guy CD, Harrison SA, Kim SU, Koot BG, Korenjak M, Kowdley KV, Lacaille F, Loomba R, Mitchell-Thain R, Morgan TR, Powell EE, Roden M, Romero-Gómez M, Silva M, Singh SP, Sookoian SC, Spearman CW, Tiniakos D, Valenti L, Vos MB, Wong VW, Xanthakos S, Yilmaz Y, Younossi Z, Hobbs A, Villota-Rivas M, Newsome PN; NAFLD Nomenclature consensus group. A multisociety Delphi consensus statement on new fatty liver disease nomenclature.Hepatology. 2023;78:1966-1986.
[RCA] [PubMed] [DOI] [Full Text][Cited by in Crossref: 2198][Cited by in RCA: 1983][Article Influence: 661.0][Reference Citation Analysis (2)]
Aramouni K, Assaf RK, Azar M, Jabbour K, Shaito A, Sahebkar A, Eid AA, Rizzo M, Eid AH. Infection with Helicobacter pylori may predispose to atherosclerosis: role of inflammation and thickening of intima-media of carotid arteries.Front Pharmacol. 2023;14:1285754.
[RCA] [PubMed] [DOI] [Full Text][Cited by in RCA: 27][Reference Citation Analysis (2)]
Furman D, Campisi J, Verdin E, Carrera-Bastos P, Targ S, Franceschi C, Ferrucci L, Gilroy DW, Fasano A, Miller GW, Miller AH, Mantovani A, Weyand CM, Barzilai N, Goronzy JJ, Rando TA, Effros RB, Lucia A, Kleinstreuer N, Slavich GM. Chronic inflammation in the etiology of disease across the life span.Nat Med. 2019;25:1822-1832.
[RCA] [PubMed] [DOI] [Full Text] [Full Text (PDF)][Cited by in Crossref: 4007][Cited by in RCA: 3295][Article Influence: 470.7][Reference Citation Analysis (0)]
